6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A detailed review of methimazole (Tapazole) FAERS adverse-event reports, FDA label warnings, post-market safety signals, and clinical guidance for patients and prescribers.
Complete FDA approval history of methimazole (Tapazole), including original approval, label updates, safety communications, and post-market surveillance data for hyperthyroidism treatment.
A comprehensive review of methimazole (Tapazole) global regulatory status, FDA approval history, prescribing label requirements, and post-market safety surveillance data for clinicians and patients.
A comprehensive review of FDA label changes for methimazole (Tapazole) from 2020 through 2026, covering safety communications, boxed warning revisions, and post-market surveillance data for antithyroid drug therapy.
A comprehensive review of methimazole (Tapazole) legal and patent history, FDA approval timeline, generic competition, labeling updates, and post-market safety surveillance.
A detailed comparison of how the FDA and EMA regulate methimazole (Tapazole) for hyperthyroidism, covering approval history, labeling differences, safety warnings, and post-market surveillance.